Stocks · News reference
Coherus Oncology Announces Interim Clinical Data for Tagmokitug in Esophageal Cancer
Coherus Oncology reported encouraging interim clinical data from its TREGCHECK development program, showing anti-tumor activity for tagmokitug in combination with toripalimab for solid tumors.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Coherus Oncology, Inc. (CHRS)
Filed: 2026-10-29 AccNo: 0001104659-26-119912 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Coherus Oncology Announces Participation in Upcoming Investor Conferences
Coherus Oncology, Inc. announced it will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies Global Healthcare Conference in November 2026.